Erratum to: Review: The changing face of the HIV epidemic in sub-Saharan Africa (Tropical Medicine and International Health, (2014), 19, 9, (1015–1028), 10.1111/tmi.12344);The changing face of the HIV epidemic in sub-Saharan Africa

Tropical Medicine and International Health

Volumn 19, Issue 9, 2014, Pages 1015-1028

  Mutevedzi, Portia C ^a   Newell, Marie Louise ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

antiretroviral therapy; human immunodeficiency virus; Incidence; Mortality; Prevalence; Prevention; TasP; Treatment as prevention

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TAR;

DISEASE INCIDENCE; DISEASE PREVALENCE; DISEASE TRANSMISSION; EPIDEMIC; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; MORTALITY; PUBLIC HEALTH;

AFRICA SOUTH OF THE SAHARA; ARTICLE; CIRCUMCISION; COHORT ANALYSIS; CONDOM USE; COUNSELING; DISEASE TRANSMISSION; EPIDEMIC; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION PREVENTION; PATIENT COUNSELING; POST EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; PRE-EXPOSURE PROPHYLAXIS; RISK FACTOR; SEXUAL BEHAVIOR; SURVIVAL RATE; ANTIRETROVIRAL THERAPY; ART; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCIA; LONGEVITY; MALE; MORTALIDAD; MORTALITÉ; MORTALITY; PATIENT COMPLIANCE; PREGNANCY; PREVALENCE; PREVALENCIA; PREVENCIÓN; PREVENTION; PRÉVALENCE; PRÉVENTION; REVIEW; TASP; TRAITEMENT PRÉVENTIF; TRATAMIENTO COMO PREVENCIÓN; TREATMENT AS PREVENTION; VIH;

SUB-SAHARAN AFRICA;

HUMAN IMMUNODEFICIENCY VIRUS;

ANTIRETROVIRAL THERAPY; ART; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; INCIDENCIA; MORTALIDAD; MORTALITÉ; MORTALITY; PREVALENCE; PREVALENCIA; PREVENCIÓN; PREVENTION; PRÉVALENCE; PRÉVENTION; TAR; TASP; TRAITEMENT PRÉVENTIF; TRATAMIENTO COMO PREVENCIÓN; TREATMENT AS PREVENTION; VIH;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; EPIDEMICS; FEMALE; HIV; HIV INFECTIONS; HUMANS; LONGEVITY; MALE; PATIENT COMPLIANCE; PREGNANCY;

EID: 84907299346     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12420     Document Type: Erratum

References (129)

1. Abrams EJ & Myer L (2013) Can we achieve an AIDS-free generation? Perspectives on the global campaign to eliminate new pediatric HIV infections. Journal of Acquired Immune Deficiency Syndromes 63, S208-S212.
2. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R & Puren A (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med 2, e298.
3. AVERT (2011) AVERTing HIV and AIDS: Africa HIV & AIDS statistics [Online]. http://www.avert.org/africa-hiv-aids-statistics.htm [Accessed 6 February 2013].
4. Babiker AG, Peto T, Porter K, Walker AS & Darbyshire JH (2001) Age as a determinant of survival in HIV infection. Journal of Clinical Epidemiology 54, S16-S21.
5. Bailey RC, Moses S, Parker CB et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. The Lancet 369, 643-656.
6. Bärnighausen T, Wallrauch C, Welte A et al. (2008) HIV incidence in rural South Africa: comparison of estimates from longitudinal surveillance and crosssectional cBED assay testing. PLoS ONE 3, e3640.
7. Bärnighausen T, Bloom DE & Humair S (2012) Economics of antiretroviral treatment vs circumcision for HIV prevention. PNAS 109, 21271-21276.
8. Beaten JM, Donnell D, Ndase P et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men nd women. The New England Journal of Medicine 367, 399-410.
9. Bor J, Bärnighausen T, Newell C, Tanser F & Newell ML (2011) Social exposure to an antiretroviral treatment program in rural KwaZulu-Natal. Tropical Medicine & International Health 16, 988-994.
10. Bor J, Tanser F, Newell ML & Bärnighausen T (2012) In a study of a population cohort in South Africa, HIV patients on antiretrovirals had nearly full recovery of employment. Health Affairs 31, 1459-1469.
11. Bor J, Herbst K, Newell ML & Bärnighausen T (2013) Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 339, 961-965.
12. Braunstein SL, Van De Wijgert JH & Nash D (2009) HIV incidence in sub-Saharan Africa: a review of available data with implications for surveillance and prevention planning. AIDS Reviews 11, 140-156.
13. Christensen K, Doblhammer G, Rau R & Vaupel JW (2009) Ageing populations: the challenges ahead. The Lancet 374, 1196-1208.
14. Cohen MS, Chen YQ, McCauley M et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. The New England Journal of Medicine 365, 493-505.
15. Collaborative Group on AIDS Incubation and HIV Surveillance (2000) Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. The Lancet 355, 1131-1137.
16. Cooke GS, Tanser F, Bärnighausen T & Newell ML (2010) Population uptake of antiretroviral treatment through primary care in rural South Africa. BMC Public Health 10, 585.
17. Corey L, Wald A, Celum CL & Quinn TC (2004) The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. Journal of Acquired Immune Deficiency Syndromes 35, 435-445.
18. Cornell M, Technau K, Fairall L et al. (2009) Monitoring the South African national antiretroviral treatment programme 2003-2007: the IeDEA Southern Africa collaboration. South African Medical Journal 99, 653-660.
19. Davies DF & Shock NW (1950) Age changes glomerular filtration rate, effective renal plasma flow and tubular excretory capacity in adult males. Journal of Clinical Investigation 29, 496-507.
20. De Cock KM & El-Sadr WM (2013) When to start ART in Africa - an urgent research priority. The New England Journal of Medicine 368, 886-889.
21. Delany S, Mlaba N, Clayton T et al. (2009) Impact of Aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randimised placebo-controlled trial in South Africa. AIDS 23, 461-469.
22. Doherty M, Ford N, Vitoria M, Weiler G & Hirnschall G (2013) The 2013 WHO guidelines for antiretroviral therapy: evidence-based recommendations to face new epidemic realities. Current Opinion in HIV AIDS 8, 528-534.
23. Doyle AM, Ross DA, Maganja K et al. (2010) Long-term biological and behavioural impact of an adolescent sexual health intervention in Tanzania: follow-up survey of the community-based MEMA kwa Vijana Trial. PLoS Med 7, e1000287.
24. Egger M (2013) Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-and high-income countries. Journal of Acquired Immune Deficiency Syndromes 65, e8-e16.
25. Fairall LR, Bachmann MO, Louwagie GM et al. (2008) Effectiveness of antiretroviral treatment in a South African program: a cohort study. Archives of Internal Medicine 168, 86-93.
26. Ferradini L, Jeannin A, Pinoges L et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. The Lancet 367, 1335-1341.
27. Ford N, Vitoria M, Hirnschall G & Doherty M (2013) Getting to zero HIV deaths: progress, challenges and ways forward. Journal of the International AIDS Society 16, 18927.
28. Gebo KA (2008) Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly. Aging Health 4, 615-627.
29. Gebo KA & Justice A (2009) HIV infection in the elderly. Current Infectious Disease Reports 11, 246-254.
30. Grabar S, Weiss L & Costagliola D (2006) HIV infection in older patients in the HAART era. Journal of Antimicrobial Chemotherapy 57, 4-7.
31. Granich RM, Gilks CF, Dye C, De Cock KM & Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. The Lancet 373, 48-57.
32. Grant RM (2010) Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clinical Infectious Diseases 50, S96-S101.
33. Gray RH & Wawer MJ (2008) Reassessing the hypothesis on STI control for HIV prevention. The Lancet 371, 2064-2065.
34. Gray RH, Kigozi G, Serwadda D et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised control trial. The Lancet 369, 657-666.
35. Greig J, Carrillo CE, O'Brian D, Mills EJ & Ford N (2012) Association between older age and adverse outcomes on antiretroviral therapy: a cohort analysis of programme data from nine countries in sub-Saharan Africa. AIDS 26 (Suppl 1), S31-7.
36. Hammer MD (2011) Antiretroviral treatment as prevention. The New England Journal of Medicine 365, 561-562.
37. Harrison A, Newell ML, Imrie J & Hoddinott G (2010) HIV prevention for South African Youth: which interventions work? A systematic review of current evidence. BMJ Public Health 10, 1471-2458.
38. Herbst AJ, Cooke GS, Bärnighausen T, Kanykany A, Tanser F & Newell ML (2009) Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bulletin of the World Health Organization 87, 754-762.
39. Herbst AJ, Mafojane T & Newell ML (2011) Verbal autopsy-based cause-specific mortality trends in rural KwaZulu-Natal, South Africa 2000-2009. Population Health Metrics 9, 47.
40. Hoffmann CJ, Schomaker M, Fox MP et al. (2013) CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa. Journal of Acquired Immune Deficiency Syndromes 63, 34-41.
41. Hogan DR, Salomon JA, Canning D, Hammit JK, Zaslavsky AM & Barnighausen T (2012) National HIV prevalence estimates for sub-Sharan Africa: controlling selection bias with Heckman-type selection models. Sexually Transmitted Infections 88, i17-i23.
42. Hontelez JA, De Vlas SJ, Tanser F et al. (2011) The impact of the New WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS ONE 6, e21919.
43. Hontelez JAC, De Vlas SJ, Baltussen R et al. (2012) The impact of antiretroviral treatment on age composition iof the HIV epidemic in sub-Saharan Africa. AIDS 26, S19-S30.
44. Hontelez JAC, Lurie M, Bärnighausen T et al. (2013) Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study. PLoS Med 10, e1001534.
45. Houlihan CF, Bland RM, Mutevedzi PC et al. (2011) Cohort profile: Hlabisa HIV treatment and care programme. International Journal of Epidemiology 40, 318-326.
46. IeDEA (2008) Long-term immunologic response to antiretroviral therapy in low-income countries: Collaborative analysis of prospective studies: The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration of the International epidemiological Databases to Evaluate AIDS. AIDS 22, 2291-2302.
47. Iwuji C, Orne-Gliemann J, Tanser F et al. (2013) Evaluation of the impact of immediate versus WHO recommendations-guided ART initiation on HIV incidence. The ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, Kwazulu-Natal, South Africa: study protocol for a randomised controlled trial. Trials 14, 230.
48. Jamison DT, Summers LH, Alleyne G et al. (2013) Global health 2035: a world converging within a generation. The Lancet 382, 1898-1955.
49. Johnson LF, Hallett TB, Rehle T & Dorrington RE (2012) The effect of changes in condom usage and antiretroviral treatment coverage on human immunodeficiency virus incidence in South Africa: a model-based analysis. Journal of the Royal Society, Interface (online publication).
50. Johnson LF, Mossong J, Dorrington RE et al. (2013) Life expectancies of South African Adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 10, e1001418.
51. Karim Q, Karim SS, Frohlich JA, Grobler AC, Baxter C & Mansoor LE (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174.
52. Karim QA, Kharsany AB, Frohlich JA et al. (2012) HIV incidence in young girls in KwaZulu-Natal, South Africa - public health imperative for their inclusion in HIV biomedical intervention trial. AIDS and Behavior 16, 1870-1876.
53. Keiser O, Anastos K, Schechter M et al. (2008) Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Tropical Medicine & International Health 13, 870-879.
54. Kerber KJ, Lawn JE, Johnson LF et al. (2013) South African child deaths 1990-2011: have HIV services reversed the trend enough to meet Millennium Development Goal 4? AIDS 27, 2637-2648.
55. Lawn SD, Kranzer K & Wood R (2009) Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clinics in Chest Medicine 30, 685-699.
56. Le T, Wright EJ, Smith DM et al. (2013) Enhanced CD4+ T-Cell recovery with earlier HIV-1 antiretroviral therapy. The New England Journal of Medicine 368, 218-230.
57. Lessells RJ, Mutevedzi PC, Cooke GS & Newell ML (2011) Retention in care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. Journal of Acquired Immune Deficiency Syndromes 56, e79-e86.
58. Lessells RJ, Mutevedzi PC, Iwuji C & Newell ML (2014) Reduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria. Journal of Acquired Immune Deficiency Syndromes 65, e17-e24.
59. Maheswaran H, Thulare H, Stanistreet D, Tanser F & Newell ML (2012) Starting a home and mobile HIV testing service in a rural area of South Africa. Journal of Acquired Immune Deficiency Syndromes 59, e43-e46.
60. Manasa J, McGrath N, Lessells R, Skingsley A, Newell ML & De Oliveira T (2013) High levels of drug resistance after failure of first-line antiretroviral therapy in rural South Africa: impact on standardised second-line regimens. PLoS ONE 8, e72152.
61. Marston M, Newell M, Crampin A et al. (2013) Is the risk of HIV acquisition increased during and immediately after pregnancy? A secondary analysis of pooled HIV community-based studies from the ALPHA networ. PLoS ONE 8, e82219.
62. McGrath N, Eaton JW, Bärnighausen T, Tanser F & Newell ML (2013a) Sexual behaviour in a rural high HIV prevalence South African community: time trends in the era of ART. AIDS 27, 2461-2470.
63. McGrath N, Richter L & Newell ML (2013b) Sexual risk after HIV diagnosis: a comparison of pre-ART individuals with CD4 > 500 cells/μl and ART-eligible individuals in an HIV treatment and care programme in rural KwaZulu-Natal, South Africa. Journal of the International AIDS Society 16, 18048.
64. Mills EJ, Bakanda C, Birungi J et al. (2011) Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Annals of Internal Medicine 155, 209-216.
65. Mossong J, Grapsa E, Tanser F, Barnighausen T & Newell M (2013) Modelling HIV incidence and survival from age-specific seroprevalence after antiretroviral treatment scale-up in rural South Africa. AIDS 27, 2471-2479.
66. Mutevedzi PC & Newell ML (2011) A missing piece in the puzzle: HIV in mature adults in sub-Saharan Africa. Future Virology 6, 755-767.
67. Mutevedzi PC, Lessells RJ, Heller T, Barnighausen T, Cooke GS & Newell ML (2010) Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes? Bulletin of the World Health Organization 88, 593-600.
68. Mutevedzi PC, Lessells RJ, Rodger AJ & Newell ML (2011) Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South Africa. PLoS ONE 6, e21795.
69. Mutevedzi P, Rodger AJ, Kowal P, Nyirenda M & Newell ML (2013) Decreased chronic morbidity but elevated HIV associated cytokine levels in HIV-infected older adults receiving HIV treatment: benefit of enhanced access to care? PLoS ONE 8, e77379.
70. Nabukalu D, Klipstein-Grobusch K, Herbst K & Newell ML (2013) Mortality in women of reproductive age in rural South Africa. Global Health Action 6, doi: 10.3402/gha.v6i0.22834
71. Nakagawa F, May M & Phillips A (2013) Life expectancy living with HIV: recent estimates and future implications. Current Opinion in Infectious Diseases 26, 17-25.
72. Naswa S & Marfatia YS (2011) Pre-exposure prophylaxis of HIV. Indian Journal of Sexually Transmitted Diseases 32, 1-8.
73. Ndirangu J, Newell ML, Tanser F, Herbst AJ & Bland R (2010) Decline in early life mortality in a high HIV prevalence rural area of South Africa: evidence of HIV prevention or treatment impact? AIDS 24, 593-602.
74. Ndirangu J, Newell ML, Thorne C & Bland R (2012) Treating HIV infected mothers reduces mortality in children under 5 years of age to levels seen in children of HIV uninfected mothers: evidence from rural South Africa. Antiviral Therapy 17, 81-90.
75. Negin J & Cumming RG (2010) HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing data. Bulletin of the World Health Organization 88, 847-853.
76. Negin J, Barnighausen T, Lundgren JD & Mills EJ (2012a) Aging with HIV in Africa: the challenges of living longer. AIDS 26, S1-S5.
77. Negin J, Martiniuk A, Cumming RG et al. (2012b) Prevalence of HIV and chronic comorbidities among older adults. AIDS 26, S55-S63.
78. Nel A, Mabude Z, Smit J et al. (2012) HIV Incidence Remains High in KwaZulu-Natal, South Africa: Evidence from Three Districts. PLoS ONE 7, e35278.
79. Nguyen H & Holodniy M (2008) HIV infection if the elderly. Clinical Interventions in Aging 3, 453-472.
80. Nylor K, Li G & Vallejo AN (2005) The influence of age on T cell generation and TCR diversity. Journal of Immunology 174, 7446-7452.
81. Phakathi Z, Van Rooyen H, Fritz K & Richter L (2011) The influence of antiretroviral treatment on willingness to test: a qualitative study in rural KwaZulu-Natal, South Africa. African Journal of AIDS Research 10, 173-180.
82. Plazy M, Dray-Spira R, Orne-Gliemann J, Dabis F & Newell ML (in press) Continuum in HIV care from entry to ART initiation in a large HIV treatment and care programme in rural KwaZulu-Natal, South Africa. Tropical Medicine & International Health 19, 680-689.
83. Pronyk PM, Hargreaves JR, Kim JC et al. (2006) Effect of a structural intervention for the prevention of intimate-partner violence and HIV in rural South Africa: a cluster randomised trial. The Lancet 368, 1973-1983.
84. Reynolds SJ, Makumbi F, Nakigozi G et al. (2011) HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 25, 473-477.
85. Rosen S & Fox MP (2011) Retention in HIV Care between Testing and Treatment in Sub-Saharan Africa: A Systematic Review. PLoS Med 8, e1001056.
86. Rosenberg N, Westreich D, Miller W et al. (2013) Assessing the effect of HIV counseling and testing on HIV acquisition among South African youth. AIDS 27, 2765-2773.
87. Sabin CA, Smith CJ, Delpech V et al. (2009) The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. HIV Medicine 10, 35-43.
88. Severe P, Juste MAJ, Ambroise A et al. (2010) Early versus standard antiretroviral therapy for HIV-Infected adults in Haiti. The New England Journal of Medicine 363, 257-265.
89. Shisana O (2013) HIV/AIDS in South Africa: at last the glass is half full. 6th South African AIDS conference 2013 Durban, South Africa.
90. Shisana O, Rehle T, Simbayi LC et al. (2009) South African National HIV Prevalence, Incidence, Behaviour and Communication Survey 2008: A Turning Tide Among Teenagers? HSRC press, Cape Town.
91. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG & Friedland B (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. The Lancet 372, 1977-1987.
92. Stangl AL, Lloyd JK, Brady LM, Holland CE & Baral S (2013) A systematic review of interventions to reduce HIV-related stigma and discrimination from 2002 to 2013: how far have we come? Journal of the International AIDS Society 16, 18734.
93. Stats-SA (2010) Mid-Year Population Estimates. Statistics South Africa, Pretoria.
94. Stats-SA (2013) Mid-Year Population Estimates. Statistics South Africa, Pretoria, South Africa.
95. Staveteig S, Wang S, Head SK, Bradley SEK & Nybro E (2013) Demographic Patterns of HIV Testing Uptake in Sub-Saharan Africa. DHS Comparative Reports, ICF International, Calverton, MD, USA.
96. Stringer JS, Zulu I, Levy J et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296, 782-793.
97. Suksomboon N, Poolsup N & Ket-Aim S (2007) Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. Journal of Clinical Pharmacy and Therapeutics 32, 293-311.
98. Suthar AB, Ford N, Bachanas PJ et al. (2013) Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med 10, e1001496.
99. Tanser F, Bärnighausen T, Graspar E, Zaidi J & Newell ML (2013a) High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-NAtal, South Africa. Science 339, 966-971.
100. Tanser F, Jones KG, Viljoen J, Imrie J, Grapsa E & Newell ML (2013b) Human Papillomavirus seropositivity and subsequent risk of HIV acquistion in rural South African women. Sexually Transmitted Diseases 40, 601-608.
101. The Kesho Bora Study Group (2011) Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. The Lancet 11, 171-180.
102. Thior I, Lockman S, Smeaton LM et al. (2006) Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 296, 794-805.
103. Todd J, Glynn JR, Marston M et al. (2007) Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy. AIDS 21 (Suppl. 6), S55-S63.
104. Toure S, Kouadio B, Seyler C et al. (2008) Rapid scaling-up of antiretroviral therapy in 10, 000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 22, 873-882.
105. UNAIDS (2002) Global summary of the HIV/AIDS epidemic.
106. UNAIDS (2006) Report on the global AIDS epidemic: executive summary.
107. UNAIDS (2010) UNAIDS report on the global AIDS epidemic: HIV prevalence map [Online]. http://www.unaids.org/globalreport/HIV_prevalence:map.htm [Accessed 21 May 2013].
108. UNAIDS (2011) World AIDS day report [Online]. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdf [Accessed 28 May 2013].
109. UNAIDS (2012a) UNAIDS Report on the Global AIDS Epidemic. UNAIDS, Geneva.
110. UNAIDS (2012b) UNAIDS World AIDS day report.
111. UNAIDS (2012c) Global HIV response update: epidemic update and health sector progress towards universal access.
112. UNAIDS (2013a) Regional support team for Eastern and Southern Africa [Online]. http://www.unaidsrstesa.org/region/countries/south-africa#5 [Accessed 28 May 2013 2013].
113. UNAIDS (2013b) UNAIDS report on the global AIDS epidemic.
114. UNAIDS (2013c) UNAIDS special report update - how Africa turned AIDS around.
115. United NationsJune (2001) Declaration of commitment on HIV/AIDS: United Nations general assembly special session on HIV/AIDS.
116. UNPD (2013) United Nations population division [Online]. United Nations. http://esa.un.org/unpd/wpp/country-profiles/country-profiles_1.htm [Accessed 19 May 2013 2013].
117. Vaginal and Oral Interventions to Control the Epidemic (VOICE) (2013) Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections. Atlanta.
118. Van Damme L, Corneli A, Ahmed K et al. (2012) Preexposure prophylaxis for HIV infection among African women. The New England Journal of Medicine 367, 411-422.
119. Walker RW, Jusabani A, Aris E et al. (2013) Stroke risk factors in an incident population in urban and rural Tanzania: a prospective, community-based, case-control study. The Lancet Global Health 1, e282-e288.
120. Wallrauch C, Barnighausen T & Newell ML (2010) HIV infection of concern also in people 50 years and older in rural South Africa. South African Medical Journal 100, 812-813.
121. When to Start Consortium (2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. The Lancet 373, 1352-1363.
122. WHO (2002) Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach.
123. WHO (2010) Antiretroviral therapy for HIV infection in adults and adolescence.
124. WHO (2011) WHO Top 10 Causes of Death Fact Sheet [Online]. Geneva. http://who.int/mediacentre/factsheets/fs310/en/ [Accessed 26 May 2013].
125. WHO (2012) Service delivery approaches to HIV testing and counselling (HTC): a strategic HTC programme framework.
126. WHO (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach.
127. WHO: HIV/AIDS Programme (2012) Programmatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants.
128. Zaba B, Todd J, Biraro S et al. (2008) Diverse age patterns of HIV incidence in Africa. XVII International AIDS Conference 2008 Mexico City.
129. Zaidi J, Grapsa E, Tanser F, Newell ML & Bärnighausen T (2013) Dramatic increases in HIV prevalence after scale-up of antiretroviral treatment: a longitudinal population-based HIV surveillance study in rural KwaZulu-Natal. AIDS 27, 2301-2305.